SCHEMBL1198959

SCHEMBL1198959

COC(=O)c1cnn(C(O)c2nc(-c3cccc(C(F)(F)F)c3)cs2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 1/20 0.48
ADAM17 P78536 1/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.48
CFTR P13569 2/20 0.45
PTPRB P23467 1/20 0.43
ITGB2 P05107 2/20 0.42
ICAM1 P05362 2/20 0.42
ITGAL P20701 2/20 0.42
ITGB3 P05106 9/20 0.42
ITGA2B P08514 9/20 0.42
TRPA1 O75762 1/20 0.41
F2RL3 Q96RI0 1/20 0.41
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198037 0.82 KDM4E (0.48) SIRT5ADAM17KDM4EMEN1ALDH1A1
SCHEMBL1198509 0.80 ALDH1A1 (0.58) SIRT5ADAM17KDM4EMEN1ALDH1A1
SCHEMBL1198162 0.80 ADAM17 (0.54) SIRT5ADAM17KDM4EMEN1ALDH1A1
SCHEMBL12890178 0.80 ADAM17 (0.65) SIRT5ADAM17KDM4EMEN1ALDH1A1
SCHEMBL7215544 0.75 ALDH1A1 (0.67) SIRT5KDM4EMEN1ALDH1A1KMT2A
SCHEMBL4829035 0.72 KDM4E (0.57) SIRT5KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1198556 0.71 ALDH1A1 (0.55) SIRT5KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1198067 0.71 KDM4E (0.49) SIRT5KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1199224 0.71 KDM4E (0.49) SIRT5KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1199322 0.71 ALDH1A1 (0.66) SIRT5ADAM17KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A SIRT5 531/4885ADAM17 2972/4885KDM4E 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.